Actively Recruiting
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Led by Second Hospital of Shanxi Medical University · Updated on 2026-04-24
40
Participants Needed
6
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.
CONDITIONS
Official Title
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the informed consent form
- Confirmed small cell lung cancer of extensive stage by histology or cytology
- At least one measurable lesion by imaging studies (according to RECIST 1.1) with a long diameter of 610 mm as examined by spiral CT or MRI
- Within 3 days prior to treatment, an ECOG score of 0 to 1
- No prior antitumor treatment for extensive stage disease (if the patient has previously received chemotherapy and/or radiotherapy in the limited stage of SCLC, the treatment intent must have been curative, and there must be at least a 6-month treatment-free interval between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive stage SCLC)
- Expected life span of 63 months
- Good function of vital organs
- The subject voluntarily joins this study, signs the informed consent form, has good compliance, and cooperates with follow-up.
You will not qualify if you...
- Concurrent severe respiratory diseases such as pulmonary fibrosis
- Presence of psychiatric disorders, hematologic diseases, autoimmune diseases, and severe primary diseases of the heart, brain, liver, or kidneys
- Uncontrolled active infections
- Known or suspected allergies to the study medication and its excipients
- Female patients who are pregnant or breastfeeding, or women of childbearing potential with a positive baseline pregnancy test
- Prior use of antitumor treatment targeting the PD-(L)1 pathway
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Jincheng General Hospital
Jincheng, Shanxi, China, 048000
Actively Recruiting
2
Jinzhong third people's hospital
Jinzhong, Shanxi, China, 032000
Actively Recruiting
3
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China, 030000
Actively Recruiting
4
Shanxi Bethune Hospital
Taiyuan, Shanxi, China, 030000
Actively Recruiting
5
Shanxi Hospital of Traditional Chinese Medicine
Taiyuan, Shanxi, China, 030000
Actively Recruiting
6
TISCO General Hospital
Taiyuan, Shanxi, China, 030000
Actively Recruiting
Research Team
G
Gang Jin, Dr.
CONTACT
C
Chen Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here